Free Trial
→ This picture could hold the secret to the market's next move. (From Weiss Ratings) (Ad) Buy TALS Stock  Free TALS Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Talaris Therapeutics (TALS) Financials

Talaris Therapeutics logo
Compare
Annual Income Statements for Talaris Therapeutics

Annual Income Statements for Talaris Therapeutics

This table shows Talaris Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -20 -42 -73
Consolidated Net Income / (Loss)		 -20 -42 -73
Net Income / (Loss) Continuing Operations		 -20 -42 -73
Total Pre-Tax Income 		-20 -45 -90
Total Operating Income		 -20 -45 -90
Total Gross Profit		 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 20 45 90
Selling, General & Admin Expense		 2.18 13 23
Research & Development Expense		 18 32 67
Total Other Income / (Expense), net		 0.00 0.00 0.00
Other Gains / (Losses), net		 0.00 3.29 17
Basic Earnings per Share		 ($22.46) ($8.87) ($2.89)
Weighted Average Basic Shares Outstanding		 877K 4.75M 25.35M
Diluted Earnings per Share		 ($22.46) ($8.87) ($2.89)
Weighted Average Diluted Shares Outstanding		 877K 4.75M 25.35M
Weighted Average Basic & Diluted Shares Outstanding		 42.02M 25.65M 25.69M

Quarterly Income Statements for Talaris Therapeutics

This table shows Talaris Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -19 36 -7.50 -16 -5.59 -13 -13 -17 -20 -22
Consolidated Net Income / (Loss)		 -19 36 -7.50 -16 -5.59 -13 -13 -17 -20 -22
Net Income / (Loss) Continuing Operations		 -19 36 -7.50 -16 -5.59 -13 -13 -17 -20 -22
Total Pre-Tax Income 		-19 36 -7.50 -16 -6.64 -15 -13 -17 -20 -39
Total Operating Income		 -20 37 -7.50 -16 -6.64 -15 -18 -22 -24 -26
Total Operating Expenses		 20 -37 7.50 16 6.64 15 18 22 24 26
Selling, General & Admin Expense		 4.84 -12 1.37 1.92 2.88 6.88 6.14 6.24 5.11 5.26
Research & Development Expense		 15 -25 6.14 14 3.76 8.02 11 16 19 21
Total Other Income / (Expense), net		 0.73 -1.21 0.00 0.25 0.00 -0.25 4.21 4.48 4.26 -13
Basic Earnings per Share		 ($4.59) ($16.98) ($8.28) ($16.29) ($5.16) $20.86 ($0.55) ($0.68) ($0.78) ($0.88)
Weighted Average Basic Shares Outstanding		 4.14M 877K 906K 990K 1.08M 4.75M 24.08M 25.72M 25.77M 25.35M
Diluted Earnings per Share		 ($4.59) ($16.98) ($8.28) ($16.29) ($5.16) $20.86 ($0.55) ($0.68) ($0.78) ($0.88)
Weighted Average Diluted Shares Outstanding		 4.14M 877K 906K 990K 1.08M 4.75M 24.08M 25.72M 25.77M 25.35M
Weighted Average Basic & Diluted Shares Outstanding		 41.72M 42.02M 42.17M 42.76M 20.34M 25.65M 25.65M 25.64M 25.64M 25.69M

Annual Cash Flow Statements for Talaris Therapeutics

This table details how cash moves in and out of Talaris Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 8.32 132 -110
Net Cash From Operating Activities		 -6.46 -28 -77
Net Cash From Continuing Operating Activities		 -6.46 -28 -77
Net Income / (Loss) Continuing Operations		 -20 -42 -73
Consolidated Net Income / (Loss)		 -20 -42 -73
Depreciation Expense		 0.01 0.03 0.04
Amortization Expense		 0.00 -0.52 -7.59
Non-Cash Adjustments To Reconcile Net Income		 12 15 6.66
Changes in Operating Assets and Liabilities, net		 0.90 -0.17 -3.15
Net Cash From Investing Activities		 -5.07 3.84 -194
Net Cash From Continuing Investing Activities		 -5.07 3.84 -194
Purchase of Property, Plant & Equipment		 -0.07 -0.06 -0.01
Purchase of Investments		 0.00 -17 -366
Sale and/or Maturity of Investments		 0.00 21 172
Net Cash From Financing Activities		 20 157 161
Net Cash From Continuing Financing Activities		 20 157 161
Repurchase of Common Equity		 - 0.00 -0.00
Issuance of Debt		 0.25 70 0.00
Issuance of Preferred Equity		 20 92 0.00
Issuance of Common Equity		 0.00 0.00 161
Other Financing Activities, net		 0.00 -5.57 0.00

Quarterly Cash Flow Statements for Talaris Therapeutics

This table details how cash moves in and out of Talaris Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -7.05 8.47 -3.82 83 -9.04 63 -42 -28 -35 -4.50
Net Cash From Operating Activities		 -13 41 -3.79 -9.54 -5.40 -9.35 -15 -18 -23 -21
Net Cash From Continuing Operating Activities		 -13 41 -3.79 -9.54 -5.40 -9.35 -15 -18 -23 -21
Net Income / (Loss) Continuing Operations		 -19 36 -7.50 -16 -5.59 -13 -13 -17 -20 -22
Consolidated Net Income / (Loss)		 -19 36 -7.50 -16 -5.59 -13 -13 -17 -20 -22
Depreciation Expense		 0.37 -1.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Amortization Expense		 -0.33 0.04 0.03 0.03 -0.06 -0.52 -1.18 -2.29 -2.15 -1.97
Non-Cash Adjustments To Reconcile Net Income		 3.28 4.02 0.39 9.26 0.79 4.26 1.37 1.79 1.72 1.78
Changes in Operating Assets and Liabilities, net		 2.27 1.83 3.28 -2.70 -0.55 -0.20 -1.81 -0.03 -2.85 1.53
Net Cash From Investing Activities		 6.30 -52 -0.02 -0.01 -0.02 3.89 -189 -10 -12 16
Net Cash From Continuing Investing Activities		 6.30 -52 -0.02 -0.01 -0.02 3.89 -189 -10 -12 16
Purchase of Property, Plant & Equipment		 -0.34 2.71 -0.02 -0.01 -0.02 -0.00 0.00 - - -0.01
Purchase of Investments		 -53 141 0.00 - - -17 -216 -43 -88 -20
Sale and/or Maturity of Investments		 59 -190 0.00 - - 21 27 32 76 36
Net Cash From Financing Activities		 0.07 20 0.00 92 -3.62 68 161 - -0.00 -0.00
Net Cash From Continuing Financing Activities		 0.07 20 0.00 92 -3.62 68 161 - -0.00 -0.00
Repurchase of Common Equity		 - - - - - 3.39 - - - -0.00

Annual Balance Sheets for Talaris Therapeutics

This table presents Talaris Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 9.10 210 309
Total Current Assets		 8.31 209 269
Cash & Equivalents		 8.26 141 31
Short-Term Investments		 0.00 62 228
Prepaid Expenses		 0.05 5.92 11
Plant, Property, & Equipment, net		 0.08 0.09 0.06
Total Noncurrent Assets		 0.71 1.34 40
Long-Term Investments		 - 0.00 37
Other Noncurrent Operating Assets		 0.71 1.34 3.47
Total Liabilities & Shareholders' Equity		 9.10 210 309
Total Liabilities		 1.71 5.25 8.95
Total Current Liabilities		 1.36 5.00 8.91
Accounts Payable		 0.40 1.07 3.58
Accrued Expenses		 0.80 3.71 5.10
Other Current Liabilities		 0.16 0.22 0.23
Total Noncurrent Liabilities		 0.34 0.25 0.04
Other Noncurrent Operating Liabilities		 0.34 0.25 0.04
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -20 205 300
Total Preferred & Common Equity		 -20 205 300
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 -20 205 300
Common Stock		 0.20 267 435
Retained Earnings		 -20 -62 -135
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.07 0.30

Quarterly Balance Sheets for Talaris Therapeutics

This table presents Talaris Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 207 173 159 151 359 345 328
Total Current Assets		 198 169 156 151 300 298 294
Cash & Equivalents		 18 24 18 67 98 70 35
Short-Term Investments		 175 142 134 80 195 219 247
Prepaid Expenses		 4.26 3.05 3.96 4.02 7.04 8.59 12
Plant, Property, & Equipment, net		 5.46 2.58 0.23 0.00 0.08 0.07 0.06
Total Noncurrent Assets		 2.95 1.16 2.44 0.01 59 47 35
Long-Term Investments		 - - - - 57 45 32
Other Noncurrent Operating Assets		 2.95 1.16 2.44 0.01 1.76 1.72 2.14
Total Liabilities & Shareholders' Equity		 207 173 159 151 359 345 328
Total Liabilities		 12 11 11 8.19 5.03 6.51 7.38
Total Current Liabilities		 9.17 10 10 8.11 4.83 6.36 7.28
Accounts Payable		 2.13 3.38 2.93 0.14 1.94 2.39 2.05
Accrued Expenses		 6.13 6.04 6.35 7.29 2.67 3.75 5.00
Other Current Liabilities		 0.91 0.75 0.85 0.68 0.22 0.22 0.23
Total Noncurrent Liabilities		 2.51 0.70 0.56 0.08 0.20 0.15 0.10
Other Noncurrent Operating Liabilities		 2.51 0.70 0.56 0.08 0.20 0.15 0.10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 195 162 148 143 354 338 321
Total Preferred & Common Equity		 195 162 148 143 354 338 321
Preferred Stock		 - - - - 0.00 0.00 0.00
Total Common Equity		 195 162 148 143 354 338 321
Common Stock		 342 349 351 352 430 432 433
Retained Earnings		 -146 -187 -202 -209 -75 -93 -113
Accumulated Other Comprehensive Income / (Loss)		 -1.22 -0.30 -0.21 -0.12 -0.25 -0.45 0.82

Annual Metrics and Ratios for Talaris Therapeutics

This table displays calculated financial ratios and metrics derived from Talaris Therapeutics' official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 0.00% 0.00% 0.00%
EBITDA Growth		 57.61% -133.04% -111.96%
EBIT Growth		 58.53% -130.49% -97.61%
NOPAT Growth		 58.53% -130.49% -97.61%
Net Income Growth		 58.81% -113.82% -73.80%
EPS Growth		 -1,269.51% 60.51% 67.42%
Operating Cash Flow Growth		 83.85% -334.83% -175.14%
Free Cash Flow Firm Growth		 58.04% -146.61% -89.50%
Invested Capital Growth		 25.56% 341.73% 144.67%
Revenue Q/Q Growth		 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 71.79% -938.78% -14.56%
EBIT Q/Q Growth		 72.27% -805.99% -13.85%
NOPAT Q/Q Growth		 72.27% -594.19% -13.85%
Net Income Q/Q Growth		 71.70% -753.79% -14.61%
EPS Q/Q Growth		 -341.26% 81.01% -115.33%
Operating Cash Flow Q/Q Growth		 88.63% -228.81% -17.55%
Free Cash Flow Firm Q/Q Growth		 71.72% -400.02% 0.24%
Invested Capital Q/Q Growth		 -186.67% 150.39% -23.38%
Profitability Metrics		 - - -
Gross Margin		 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 92.77% 81.59%
Interest Burden Percent		 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -15.75% -39.66% -28.99%
Cash Return on Invested Capital (CROIC)		 0.00% -1,661.52% -1,827.04%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -14.04% -34.59% -28.99%
Return on Equity Simple (ROE_SIMPLE)		 99.84% -20.54% -24.40%
Net Operating Profit after Tax (NOPAT)		 -14 -32 -63
NOPAT Margin		 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.69% -9.79% -4.18%
Return On Investment Capital (ROIC_SIMPLE)		 - -15.50% -20.93%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -20 -45 -90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 -46 -97
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 0.00 2.60 1.73
Price to Tangible Book Value (P/TBV)		 0.00 2.60 1.73
Price to Revenue (P/Rev)		 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 157.56 44.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.01 -0.99 -0.99
Leverage Ratio		 1.04 1.03 1.03
Compound Leverage Factor		 1.04 1.03 1.03
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 366.90% 0.00% 0.00%
Common Equity to Total Capital		 -266.90% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 5.68 60.85 34.30
Noncontrolling Interest Sharing Ratio		 10.84% 12.77% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 6.10 41.76 30.18
Quick Ratio		 6.06 40.57 28.99
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -14 -35 -66
Operating Cash Flow to CapEx		 -9,497.06% -50,144.64% -858,477.78%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -0.87 2.09 5.12
Invested Capital Turnover		 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.30 2.96 3.03
Enterprise Value (EV)		 61 329 225
Market Capitalization		 43 532 520
Book Value per Share		 ($0.47) $10.08 $11.70
Tangible Book Value per Share		 ($0.47) $10.08 $11.70
Total Capital		 7.39 205 300
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -8.26 -203 -295
Capital Expenditures (CapEx)		 0.07 0.06 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.31 0.92 1.63
Debt-free Net Working Capital (DFNWC)		 6.95 204 260
Net Working Capital (NWC)		 6.95 204 260
Net Nonoperating Expense (NNE)		 5.91 10 10
Net Nonoperating Obligations (NNO)		 -8.26 -203 -295
Total Depreciation and Amortization (D&A)		 0.01 -0.49 -7.56
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($17.90) ($8.87) ($2.89)
Adjusted Weighted Average Basic Shares Outstanding		 4.12M 4.75M 25.35M
Adjusted Diluted Earnings per Share		 ($17.90) ($8.87) ($2.89)
Adjusted Weighted Average Diluted Shares Outstanding		 4.12M 4.75M 25.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.20M 25.65M 25.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 -32 -63
Normalized NOPAT Margin		 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.01%

Quarterly Metrics and Ratios for Talaris Therapeutics

This table displays calculated financial ratios and metrics derived from Talaris Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -54.99% 354.18% 58.36% 10.39% 66.29% -142.82% -94.02% -22.83% -233.35% -80.31%
EBIT Growth		 -52.42% 356.82% 59.26% 12.41% 66.62% -140.30% -77.43% -8.42% -203.73% -73.31%
NOPAT Growth		 -51.82% 466.88% 59.26% 11.08% 66.49% -128.21% -133.50% -34.18% -267.88% -73.31%
Net Income Growth		 -46.91% 350.44% 58.91% 10.87% 70.59% -136.18% -77.43% -8.42% -260.88% -72.34%
EPS Growth		 -1,334.38% -4,453.85% -1,740.00% -3,602.27% -12.42% 222.85% 93.36% 95.83% 84.88% -104.22%
Operating Cash Flow Growth		 -32.56% 512.30% 76.71% 44.79% 59.81% -123.08% -293.64% -88.73% -334.47% -123.34%
Free Cash Flow Firm Growth		 -38.83% 452.69% 95.16% 75.55% 103.57% -136.50% -2,920.18% -519.93% -5,710.28% -57.63%
Invested Capital Growth		 9.07% 25.56% -914.77% -212.12% -515.83% 341.73% 194.15% 195.11% 260.89% 144.67%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -10.59% 281.10% -120.75% -115.61% 58.40% -130.04% -113.88% -36.49% -12.91% -24.42%
EBIT Q/Q Growth		 -8.07% 285.66% -120.30% -115.00% 58.81% -124.15% -37.80% -31.37% -15.38% -27.90%
NOPAT Q/Q Growth		 -7.65% 366.29% -114.21% -118.26% 59.43% -124.15% -39.01% -25.43% -11.23% -5.60%
Net Income Q/Q Growth		 -5.06% 287.60% -121.03% -115.00% 65.34% -130.76% -15.97% -31.37% -15.38% -10.20%
EPS Q/Q Growth		 -943.18% -269.93% 51.24% -96.74% 68.32% 504.26% -103.17% -23.64% -14.71% -12.82%
Operating Cash Flow Q/Q Growth		 22.30% 401.85% -109.35% -151.68% 43.44% -73.33% -235.41% -20.67% -30.19% 10.90%
Free Cash Flow Firm Q/Q Growth		 9.28% 362.58% -101.82% -462.81% 113.24% -2,787.09% -71.41% -15.52% -19.78% 24.50%
Invested Capital Q/Q Growth		 -72.51% -186.67% -371.91% 0.29% -1.97% 150.39% 83.79% 0.73% 72.49% -23.38%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.59% 99.78% 100.00% 100.00% 84.16% 85.25% 100.00% 100.00% 100.00% 57.37%
Interest Burden Percent		 95.92% 96.73% 100.00% 100.00% 100.00% 101.65% 100.00% 100.00% 100.00% 150.19%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -30.90% -15.75% -4.61% -3.89% 3.82% -39.66% -18.58% -20.25% -27.54% -28.99%
Cash Return on Invested Capital (CROIC)		 -5,207.63% 0.00% 0.00% 0.00% 0.00% -1,661.52% -1,215.76% -1,308.59% -988.44% -1,827.04%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -30.90% -14.04% -4.61% -3.89% 3.82% -34.59% -18.58% -20.25% -27.54% -28.99%
Return on Equity Simple (ROE_SIMPLE)		 -35.72% 0.00% -5.53% -4.70% 4.51% 0.00% -13.54% -14.57% -19.90% 0.00%
Net Operating Profit after Tax (NOPAT)		 -14 37 -5.25 -11 -4.65 -10 -12 -15 -17 -18
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.29% -1.02% -1.15% -2.60% -0.55% -2.35% -0.41% -0.87% -1.33% -1.68%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -5.08% - - - -6.02%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -20 37 -7.50 -16 -6.64 -15 -13 -17 -20 -26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -20 36 -7.46 -16 -6.70 -15 -14 -20 -22 -28
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.56 0.00 0.49 0.86 0.84 2.60 1.66 0.98 2.05 1.73
Price to Tangible Book Value (P/TBV)		 0.56 0.00 0.49 0.86 0.84 2.60 1.66 0.98 2.05 1.73
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 18.65 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 5.36% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 157.56 61.67 0.00 51.65 44.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.00 -1.01 -1.01 -1.00 -1.01 -0.99 -1.00 -1.00 -0.99 -0.99
Leverage Ratio		 1.04 1.04 1.06 1.06 1.06 1.03 1.03 1.04 1.03 1.03
Compound Leverage Factor		 1.00 1.01 1.06 1.06 1.06 1.05 1.03 1.04 1.03 1.54
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 366.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% -266.90% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.42 26.23 3.80 6.19 7.86 61.33 70.63 30.87 53.97 34.99
Noncontrolling Interest Sharing Ratio		 0.00% 10.84% 0.00% 0.00% 0.00% 12.77% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 21.61 6.10 16.59 15.41 18.64 41.76 62.17 46.87 40.33 30.18
Quick Ratio		 21.15 6.06 16.29 15.02 18.14 40.57 60.71 45.52 38.70 28.99
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -14 37 -0.67 -3.76 0.50 -13 -20 -23 -28 -21
Operating Cash Flow to CapEx		 -3,937.54% 0.00% -15,795.83% -73,392.31% -31,741.18% -467,650.00% 0.00% 0.00% 0.00% -232,100.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 1.00 -0.87 -4.08 -4.07 -4.15 2.09 3.84 3.87 6.68 5.12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.08 0.30 -4.58 -7.70 -5.15 2.96 7.93 7.94 11 3.03
Enterprise Value (EV)		 -84 61 -87 -24 -27 329 237 -4.60 345 225
Market Capitalization		 110 43 79 128 120 532 587 330 659 520
Book Value per Share		 $4.67 ($0.47) $3.88 $3.52 $3.34 $10.08 $13.81 $13.19 $12.52 $11.70
Tangible Book Value per Share		 $4.67 ($0.47) $3.88 $3.52 $3.34 $10.08 $13.81 $13.19 $12.52 $11.70
Total Capital		 195 7.39 162 148 143 205 354 338 321 300
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -194 -8.26 -166 -153 -147 -203 -350 -334 -314 -295
Capital Expenditures (CapEx)		 0.34 -2.71 0.02 0.01 0.02 0.00 0.00 0.00 0.00 0.01
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.91 -1.31 -7.13 -6.43 -4.08 0.92 2.21 2.23 4.58 1.63
Debt-free Net Working Capital (DFNWC)		 189 6.95 159 146 143 204 295 292 287 260
Net Working Capital (NWC)		 189 6.95 159 146 143 204 295 292 287 260
Net Nonoperating Expense (NNE)		 5.13 1.29 2.25 4.67 0.94 2.48 1.05 2.11 3.07 4.17
Net Nonoperating Obligations (NNO)		 -194 -8.26 -166 -153 -147 -203 -350 -334 -314 -295
Total Depreciation and Amortization (D&A)		 0.04 -0.98 0.04 0.04 -0.05 -0.51 -1.17 -2.28 -2.14 -1.96
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($4.60) ($169.80) ($5.40) ($3.50) ($1.64) $20.86 ($0.55) ($0.68) ($0.78) ($0.88)
Adjusted Weighted Average Basic Shares Outstanding		 4.14M 87.70K 4.18M 4.22M 4.27M 4.75M 24.08M 25.72M 25.77M 25.35M
Adjusted Diluted Earnings per Share		 ($4.60) ($169.80) ($5.40) ($3.50) ($1.64) $20.86 ($0.55) ($0.68) ($0.78) ($0.88)
Adjusted Weighted Average Diluted Shares Outstanding		 4.14M 87.70K 4.18M 4.22M 4.27M 4.75M 24.08M 25.72M 25.77M 25.35M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 4.17M 4.20M 4.22M 4.28M 20.34M 25.65M 25.65M 25.64M 25.64M 25.69M
Normalized Net Operating Profit after Tax (NOPAT)		 -14 26 -5.25 -11 -4.65 -10 -12 -15 -17 -18
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.01%

Frequently Asked Questions About Talaris Therapeutics' Financials

When does Talaris Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Talaris Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Talaris Therapeutics' net income changed over the last 2 years?

Talaris Therapeutics' net income appears to be on an upward trend, with a most recent value of -$73.21 million in 2024, rising from -$19.70 million in 2022. The previous period was -$42.12 million in 2023.

What is Talaris Therapeutics's operating income?
Talaris Therapeutics's total operating income in 2024 was -$89.73 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $89.73 million
How has Talaris Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Talaris Therapeutics' total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Talaris Therapeutics have?

Talaris Therapeutics' total liabilities were at $8.95 million at the end of 2024, a 70.4% increase from 2023, and a 424.9% increase since 2022.

How much cash does Talaris Therapeutics have?

In the past 2 years, Talaris Therapeutics' cash and equivalents has ranged from $8.26 million in 2022 to $140.73 million in 2023, and is currently $30.51 million as of their latest financial filing in 2024.

How has Talaris Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Talaris Therapeutics' book value per share changed from -0.47 in 2022 to 11.70 in 2024, a change of -2,574.4%.


Related Companies

This page (NASDAQ:TALS) was last updated on 5/12/2025 by MarketBeat.com Staff
From Our Partners
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Paradigm Press | Sponsored
The one deadline Elon can't afford to miss...
For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...
Brownstone Research | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
A New Economic Shift – How You Can Prepare
While everyone's focused on the Fed and interest rates... most investors are missing the real story. There'...
InvestorPlace | Sponsored
AI Boom Takes a Shocking Turn…
The AI “Gold Rush” is Here… History's repeating itself — but this time, the shovels are digital.
Crypto 101 Media | Sponsored